The Journal of Bone and Joint Surgery (American). 2005;87:1129-1136.
doi:10.2106/JBJS.D.02240
© 2005 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kokoszka, A.
Right arrow Articles by Neuwirth, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kokoszka, A.
Right arrow Articles by Neuwirth, M.
Related Collections
Right arrow Current Concepts Review
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

Current Concepts Review

Evidence-Based Review of the Role of Aprotinin in Blood Conservation During Orthopaedic Surgery

Agnieszka Kokoszka, MD1, Paul Kuflik, MD2, Fabien Bitan, MD2, Andrew Casden, MD2 and Michael Neuwirth, MD2

1 Department of Neurology, SVCMC'St. Vincent's Hospital Manhattan, 153 West 11th Street, Cronin 4, New York, NY 10011. E-mail address: agnieszka.kokoszka{at}mail.hsc.sunysb.edu
2 The Spine Institute, Beth Israel Medical Center, Phillips Ambulatory Care Center, 10 Union Square East, Suite 5P, New York, NY 10003

Investigation performed at the Spine Institute, Beth Israel Medical Center, New York, NY

The authors did not receive grants or outside funding in support of their research or preparation of this manuscript. They did not receive payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.

Aprotinin is a serine protease inhibitor with antifibrinolytic properties that has been approved as a blood-conserving drug in cardiac surgery by the United States Food and Drug Administration.

On the basis of the current evidence from Level-I trials, we make a grade-A recommendation for use of the high-dose aprotinin regimen in hip and spine surgery.

Because of conflicting data, the low-dose aprotinin therapy as well as the use of aprotinin in patients with cancer cannot be recommended (grade-I recommendation).

High-quality randomized trials are necessary to determine the optimal (and minimal) therapeutic dose of aprotinin and the optimal time of aprotinin administration during surgery.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
C. H. Nielsen
Postoperative Renal Failure After Aprotinin Infusion and Spine Operations
Anesth. Analg., October 1, 2006; 103(4): 1062 - 1063.
[Full Text] [PDF]